Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment

OBJECTIVE: We previously reported that 2 years of costimulation modulation with abatacept slowed decline of β-cell function in recent-onset type 1 diabetes (T1D). Subsequently, abatacept was discontinued and subjects were followed to determine whether there was persistence of effect. RESEARCH DESIGN...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Orban, Tihamer, Bundy, Brian, Becker, Dorothy J., DiMeglio, Linda A., Gitelman, Stephen E., Goland, Robin, Gottlieb, Peter A., Greenbaum, Carla J., Marks, Jennifer B., Monzavi, Roshanak, Moran, Antoinette, Peakman, Mark, Raskin, Philip, Russell, William E., Schatz, Desmond, Wherrett, Diane K., Wilson, Darrell M., Krischer, Jeffrey P., Skyler, Jay S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Diabetes Association 2014
Assuntos:
Emerging Technologies and Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3964491/
https://ncbi.nlm.nih.gov/pubmed/24296850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc13-0604
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados